Article in EMBO reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
19 authors.
Ivana Nikolic *Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, 28029, Spain. inikolic@cnic.es.ORCID 0000-0003-2879-8563
Irene Ruiz-Garrido *Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, 28029, Spain.
María CrespoCentro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, 28029, Spain.
Rafael Romero-BecerraCentro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, 28029, Spain.ORCID 0000-0003-3935-2647
Luis Leiva-VegaCentro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, 28029, Spain.
Alfonso MoraCentro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, 28029, Spain.ORCID 0000-0002-6397-4836
Marta LeónCentro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, 28029, Spain.
Elena RodríguezCentro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, 28029, Spain.
Magdalena LeivaCentro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, 28029, Spain.
Ana Belén Plata-GómezProgramme of Molecular Oncology, Spanish National Cancer Research Center (CNIO), Madrid, 28029, Spain.ORCID 0000-0002-6256-0084
Maria Beatriz Alvarez FloresCentro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, 28029, Spain.ORCID 0000-0002-0292-5010
Jorge L TorresDepartment of Internal Medicine, University Hospital of Salamanca-IBSAL, Department of Medicine, University of Salamanca, Salamanca, 37007, Spain.ORCID 0000-0001-6853-9115
Lourdes Hernández-CosidoBariatric Surgery Unit, Department of General Surgery, University Hospital of Salamanca, Department of Surgery, University of Salamanca, Salamanca, 37007, Spain.ORCID 0000-0003-1359-7478
Juan Antonio LópezCentro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, 28029, Spain.ORCID 0000-0002-9097-6060
Jesús VázquezCentro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, 28029, Spain.ORCID 0000-0003-1461-5092
Alejo EfeyanProgramme of Molecular Oncology, Spanish National Cancer Research Center (CNIO), Madrid, 28029, Spain.ORCID 0000-0002-3806-6799
Pilar MartinCentro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, 28029, Spain.ORCID 0000-0002-2392-1764
Miguel MarcosDepartment of Internal Medicine, University Hospital of Salamanca-IBSAL, Department of Medicine, University of Salamanca, Salamanca, 37007, Spain.ORCID 0000-0003-1269-4487
Guadalupe SabioCentro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, 28029, Spain. gsabio@cnio.es.ORCID 0000-0002-2822-0625
Funding
BBVA | Fundación BBVA (FBBVA) (Investigadores-BBVA-2017) IN[17]_BBM_BAS_0066Comunidad de Madrid (Community of Madrid) IMMUNOTHERCAN-CM S2010/BMD-2326 and B2017/BMD-3733EC | European Research Council (ERC) FP7/2007-2013 (ERC 260464)EC | FP7 | People | FP7 People: Marie-Curie Actions (FP7 People) PCOFUND-2012-600396European Foundation for the Study of Diabetes (EFSD) 2017-2019European Foundation for the Study of Diabetes (EFSD) EFSD/Lilly European Diabetes Research ProgrammeEuropean Foundation for the Study of Diabetes (EFSD) Rising Star awardEuropean Molecular Biology Organization (EMBO) EMBO YIPEuropean Molecular Biology Organization (EMBO) YIPFundación Científica Asociación Española Contra el Cáncer (AECC) AECC PROYE19047SABIFundación Científica Asociación Española Contra el Cáncer (AECC) INVES20026LEIVMinisterio de Asuntos Económicos y Transformación Digital, Gobierno de España (MINECO) BES-2017-079711Ministerio de Asuntos Económicos y Transformación Digital, Gobierno de España (MINECO) IJC2018-035390-IMinisterio de Asuntos Económicos y Transformación Digital, Gobierno de España (MINECO) SAF2015-74112-JINMinisterio de Ciencia e Innovación (MCIN) IMPACT-2021. Instituto de Salud Carlos III.Ministerio de Ciencia e Innovación (MCIN) PDC2021-121147-I00Ministerio de Ciencia e Innovación (MCIN) PGC2018-097019-B-I00Ministerio de Ciencia e Innovación (MCIN) PID2019-104399RB-I00Ministerio de Ciencia e Innovación (MCIN) PRE2020-092784Ministerio de Ciencia e Innovación (MCIN) RED2022-134397-TMinisterio de Ciencia e Innovación (MCIN) SAF2016-79126-RMinisterio de Ciencia e Innovación (MCIN) Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MICIN/AEI/10.13039/501100011033)Ministerio de Ciencia, Innovación y Universidades (MCIU) PID2022-138525OB-I00 2023- 26Ministerio de Universidades (MU) FPU17/03847
6 · The paper itself
Abstract
Obesity is characterized by low-grade inflammation, energy imbalance and impaired thermogenesis. The role of regulatory T cells (Treg) in inflammation-mediated maladaptive thermogenesis is not well established. Here, we find that the p38 pathway is a key regulator of T cell-mediated adipose tissue (AT) inflammation and browning. Mice with T cells specifically lacking the p38 activators MKK3/6 are protected against diet-induced obesity, leading to an improved metabolic profile, increased browning, and enhanced thermogenesis. We identify IL-35 as a driver of adipocyte thermogenic program through the ATF2/UCP1/FGF21 pathway. IL-35 limits CD8
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Lack of p38 activation in T cells increases IL-35 and protects against obesity by promoting thermogenesis. · full record | Socratic